Gapping up
In reaction to earnings/guidance: GNW +11.4%, GNRC +7.9%, PAYC +6.4%, CG +6.1%, THOR +4.4%, SGMO +4.2%, AKAM +3.8%, WIX +3.8%, AFSI +3.8%, ARMH +3.5%, PEP +3.4%, CRL +2.9%, TSRA +2.8%, ING +2.7%, ING +2.7%, COVS +2.5%, BDL +2.4%, WU +2.2%, EZCH +2%, MDLZ +1.9%, MOS +1.4%, FSRV +1.3%, (also announces plan to separate into two independent public companies), ZTS +1.3%, VOYA +1.1%, NNA +0.6%, TWX +0.5%
M&A news: INXN +12.5% (InterXion and TelecityGroup reach non-binding agreement on all-share merger), CHS +9.3% (WSJ reporting that Sycamore Partners may buy Chico's)
Other news: BLDP +36.1% (entered into a Technology Solutions transaction with Volkswagen Group (VLKAY) for an aggregate amount of ~$80 mln), PME +34.2% (Pingtan Marine Enterprise has entered into an Investment Agreement with China Agriculture Industry Development Fund pursuant to which China Agriculture will invest ~$64.0 million into Pingtan Fishing for an 8% equity interest in Pingtan Fishing's operating company), HTBX +20.5% (presents positive preclinical data on a novel approach to combination immunotherapy at the Keystone Symposia on tumor immunology), MSTX +11.6% (announces Vepoloxamer alone and in combination with tPA improved neurologic function and reduced brain tissue loss compared to tPA alone and saline controls), PSTR+7% (co engaged Evercore Group to explore strategic alternatives), ONCY +6.5% (confirms receipt of orphan drug designation from the FDA for REOLYSIN, for the treatment of ovarian cancer), NLST +6.3% (announced a U.S. Court of Appeals decision denying an emergency motion from Diablo Technologies), FCEL +5.5% (in sympathy with BLDP), PLUG +4.9% (in sympathy with BLDP), PLKI +3.6% (to replace TDY in the S&P SmallCap 600), CVM +3.4% (announced that the Philippines Regulatory Agency (PFDA) cleared co to commence patient enrollment of Phase III head and neck cancer trial of Multikine in the Philippines), EGY +3.2% (announced first production from Etame 10-H, the second development well drilled from the newly installed Etame platform, offshore Gabon), DHRM +3% (announces strategic cooperation agreement in China with the Clinical Sleep Medicine Center of the Air Force General Hospital), HLF +2.5% (in symp with NUS), UNIS +2% (CEO on Fast Money), CSIQ +1.4% (in symp with FSLR), FSLR +1.3% (late move higher on Apple partnership news), BT +1.3% (rival b sky b outbid co for Premier League TV right),QIWI +1.3% (QIWI and MegaFon announce strategic partnership by launching a co-branded wallet), TDY +1% (to replace CVD in the S&P MidCap 400)
Analyst comments: NUS +3.4% (upgraded to Buy from Neutral at Citigroup), YELP +1.9% (upgraded to Buy from Hold at Brean Capital), VMW +0.6% (upgraded to Mkt Perform from Underperform at Bernstein)
In reaction to earnings/guidance: GNW +11.4%, GNRC +7.9%, PAYC +6.4%, CG +6.1%, THOR +4.4%, SGMO +4.2%, AKAM +3.8%, WIX +3.8%, AFSI +3.8%, ARMH +3.5%, PEP +3.4%, CRL +2.9%, TSRA +2.8%, ING +2.7%, ING +2.7%, COVS +2.5%, BDL +2.4%, WU +2.2%, EZCH +2%, MDLZ +1.9%, MOS +1.4%, FSRV +1.3%, (also announces plan to separate into two independent public companies), ZTS +1.3%, VOYA +1.1%, NNA +0.6%, TWX +0.5%
M&A news: INXN +12.5% (InterXion and TelecityGroup reach non-binding agreement on all-share merger), CHS +9.3% (WSJ reporting that Sycamore Partners may buy Chico's)
Other news: BLDP +36.1% (entered into a Technology Solutions transaction with Volkswagen Group (VLKAY) for an aggregate amount of ~$80 mln), PME +34.2% (Pingtan Marine Enterprise has entered into an Investment Agreement with China Agriculture Industry Development Fund pursuant to which China Agriculture will invest ~$64.0 million into Pingtan Fishing for an 8% equity interest in Pingtan Fishing's operating company), HTBX +20.5% (presents positive preclinical data on a novel approach to combination immunotherapy at the Keystone Symposia on tumor immunology), MSTX +11.6% (announces Vepoloxamer alone and in combination with tPA improved neurologic function and reduced brain tissue loss compared to tPA alone and saline controls), PSTR+7% (co engaged Evercore Group to explore strategic alternatives), ONCY +6.5% (confirms receipt of orphan drug designation from the FDA for REOLYSIN, for the treatment of ovarian cancer), NLST +6.3% (announced a U.S. Court of Appeals decision denying an emergency motion from Diablo Technologies), FCEL +5.5% (in sympathy with BLDP), PLUG +4.9% (in sympathy with BLDP), PLKI +3.6% (to replace TDY in the S&P SmallCap 600), CVM +3.4% (announced that the Philippines Regulatory Agency (PFDA) cleared co to commence patient enrollment of Phase III head and neck cancer trial of Multikine in the Philippines), EGY +3.2% (announced first production from Etame 10-H, the second development well drilled from the newly installed Etame platform, offshore Gabon), DHRM +3% (announces strategic cooperation agreement in China with the Clinical Sleep Medicine Center of the Air Force General Hospital), HLF +2.5% (in symp with NUS), UNIS +2% (CEO on Fast Money), CSIQ +1.4% (in symp with FSLR), FSLR +1.3% (late move higher on Apple partnership news), BT +1.3% (rival b sky b outbid co for Premier League TV right),QIWI +1.3% (QIWI and MegaFon announce strategic partnership by launching a co-branded wallet), TDY +1% (to replace CVD in the S&P MidCap 400)
Analyst comments: NUS +3.4% (upgraded to Buy from Neutral at Citigroup), YELP +1.9% (upgraded to Buy from Hold at Brean Capital), VMW +0.6% (upgraded to Mkt Perform from Underperform at Bernstein)